



**NMS Labs**

**CONFIDENTIAL**

200 Welsh Road, Horsham, PA 19044-2208  
Phone: (215) 657-4900 Fax: (215) 657-2972  
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

**Demo Report**

**Report Issued** 03/30/2020 12:30  
**Last Report Issued** 05/11/2016 09:41

**88888**  
Clinical Example Report  
Attn: Example Reports  
200 Welsh Road  
Horsham, PA 19044

**Patient Name** 2457SP-POS  
**Patient ID** 2457SP-POS  
**Chain** 16000653  
**Age** Not Given **DOB** Not Given  
**Gender** Not Given  
**Workorder** 16000653  
**Received** 05/04/2016 13:32

**Sample ID** 16000653-001  
**Matrix** Serum or Plasma  
**Patient Name** 2457SP-POS  
**Patient ID** 2457SP-POS  
**Container Type** Clear vial

**Collect Dt/Tm** Not Given  
**Source** Not Given

**Approx Vol/Weight** Not Given

**Receipt Notes** None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

**2457SP Isavuconazole, Serum/Plasma**

Analysis by High Performance Liquid Chromatography/  
Tandem Mass Spectrometry (LC-MS/MS)

Isavuconazole	5.0	mcg/mL	0.050	
---------------	-----	--------	-------	--

Synonym(s): BAL4815; BAL8557; Cresemba®  
Single oral doses of 100, 200, and 400 mg of isavuconazole as a prodrug resulted in peak plasma concentrations of 1.45 (+/- 0.177) mcg/mL, 2.59 (+/- 0.449) mcg/mL, and 5.57 (+/- 0.212) mcg/mL, respectively. Peak plasma concentrations were reached between 1.8-3 hrs after administration.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.